507 related articles for article (PubMed ID: 18725849)
1. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
3. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
4. Decision analysis of tamoxifen for the prevention of invasive breast cancer.
Grann VR; Sundararajan V; Jacobson JS; Whang W; Heitjan DF; Antman KH; Neugut AI
Cancer J; 2000; 6(3):169-78. PubMed ID: 10882333
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen for breast cancer prevention: a framework for clinical decisions.
Cykert S; Phifer N; Hansen C
Obstet Gynecol; 2004 Sep; 104(3):433-42. PubMed ID: 15339751
[TBL] [Abstract][Full Text] [Related]
7. The cost effectiveness of tamoxifen in the prevention of breast cancer.
Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan.
Okubo I; Kondo M; Toi M; Ochiai T; Miki S
Gan To Kagaku Ryoho; 2005 Mar; 32(3):351-63. PubMed ID: 15791818
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis.
Ozanne EM; Esserman LJ
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2043-52. PubMed ID: 15598759
[TBL] [Abstract][Full Text] [Related]
11. Preferences for health outcomes and cost-utility analysis.
Torrance GW
Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database.
Yang JJ; Park SK; Cho LY; Han W; Park B; Kim H; Lee KS; Hahn SK; Cho SI; Ahn SH; Noh DY;
Clin Ther; 2010 Jun; 32(6):1122-38. PubMed ID: 20637966
[TBL] [Abstract][Full Text] [Related]
13. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.
Karnon J
Health Econ; 2003 Oct; 12(10):837-48. PubMed ID: 14508868
[TBL] [Abstract][Full Text] [Related]
14. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
[TBL] [Abstract][Full Text] [Related]
15. Economic and cost-effectiveness issues in breast cancer treatment.
Hillner BE
Semin Oncol; 1996 Feb; 23(1 Suppl 2):98-104. PubMed ID: 8614853
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer; 2008 Mar; 112(5):1058-65. PubMed ID: 18186497
[TBL] [Abstract][Full Text] [Related]
17. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM
J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model.
Lux MP; Hartmann M; Jackisch C; Raab G; Schneeweiss A; Possinger K; Oyee J; Harbeck N
Breast Cancer Res Treat; 2009 Sep; 117(2):305-17. PubMed ID: 19130218
[TBL] [Abstract][Full Text] [Related]
19. The benefits and costs of tamoxifen for breast cancer prevention.
Eckermann SD; Martin AJ; Stockler MR; Simes RJ
Aust N Z J Public Health; 2003; 27(1):34-40. PubMed ID: 14705265
[TBL] [Abstract][Full Text] [Related]
20. Stroke risk and tamoxifen therapy for breast cancer.
Geiger AM; Fischberg GM; Chen W; Bernstein L
J Natl Cancer Inst; 2004 Oct; 96(20):1528-36. PubMed ID: 15494603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
